by Peter Ciszewski | Aug 10, 2017
Philippe M. Maitre, Executive Vice President, US Operations discusses Onxeo and the company’s focus on orphan oncology products. Onxeo was created through the merger of BioAlliance Pharma, a French innovative company based in Paris specializing in the...
by Peter Ciszewski | Aug 8, 2017
Overview X-linked juvenile retinoschisis (XLRS) is a genetic ocular disease characterized by reduced visual acuity in males due to juvenile macular degeneration. Symptoms X-linked juvenile retinoschisis manifests with poor vision and reading difficulties. In severe...
by Peter Ciszewski | Aug 8, 2017
Overview Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by high blood pressure (hypertension) in the arteries of the lungs (pulmonary artery) for no apparent reason. The pulmonary arteries are the blood vessels that carry blood...
by Peter Ciszewski | Aug 8, 2017
Kadmon Holdings announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to tesevatinib for the treatment of non-small cell lung cancer (NSCLC) with epithelial growth factor receptor (EGFR)-activating mutations. The drug was...
